Wilmot Cancer Institute / Research / Biobank & Biospecimen / Publications

Publications

BSR Acknowledgment

The BSR is funded by Wilmot Cancer Institute. Any scholarly works (manuscripts, posters, presentations) that leverage BSR materials and/or services for data generation should acknowledge both Wilmot Cancer Institute and the BSR. Proper recognition allows us to measure the impact of our work and supports our initiatives in obtaining sponsored funding. In addition, any BSR personnel who make a substantial intellectual or experimental contribution are deserving of further recognition as co-author on scholarly works at the discretion of the Director and Principal Investigator. Please send citations of any published material to the BSR Director.

Example: [Sample/Service] was provided by the Wilmot Biobank Shared Resource at the University of Rochester Medical Center, which receives financial support from sponsor name (grant number). We especially thank [staff name], for their assistance with [technique/technology].

BSR Description for Grant Proposals

The Biobank Shared Resource (BSR) supports human tissue research at the Wilmot Cancer Institute by offering access to an extensive catalog of clinically annotated biospecimens and comprehensive clinical study consultation and support. Within the BSR, the Wilmot Biobank (WBB) currently inventories over 10,000 specimens procured from approximately 1,000 cases. Sample derivatives include formalin-fixed paraffin-embedded (FFPE) and cryopreserved tumor, adjacent normal, and lymph node tissues, as well as paired blood derivatives (plasma, serum, buffycoat). Aside from prospective tissue banking, the WBB also supports study-specific subject enrollment and tissue collection based on project needs. Detailed standard operating procedures are followed for every procurement, including the implementation of Standard PREanalytical Code (SPREC) annotation for preanalytical quality control. Specimen inventory and corresponding de-identified subject/case information are securely accessible to users through the Bio-Lab Informatics System (BLIS) web-based interface. The WBB BLIS interface reports the subject/disease/sample-level data elements recommended by Biospecimen Reporting for Improved Study Quality (BRISQ) guidelines, and more comprehensive data manifests are made available to users on a case-by-case basis upon request.

Highlights

2023

Uccello TP, Lesch ML, Ullman NA, Kintzel SA, Gradzewicz LB, Velagaleti T, Fleming FJ, Mills BN, Murphy JD, Garrett-Larsen J, Qiu H, Drage MG, Ye J, Gavras NW, Johnston CJ, Love TMT, Repasky EA, Linehan DC, Lord EM, Gerber SA. Radiation Therapy Exacerbates Tumor-Promoting Innervation and Nerve Signaling in Rectal Cancer. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):733-745. doi: 10.1016/j.ijrobp.2022.09.080. Epub 2022 Oct 4. PMID: 36202180; PMCID: PMC9898185.
Williams HL, Dias Costa A, Zhang J, Raghavan S, Winter PS, Kapner KS, Ginebaugh SP, Väyrynen SA, Väyrynen JP, Yuan C, Navia AW, Wang J, Yang A, Bosse TL, Kalekar RL, Lowder KE, Lau MC, Elganainy D, Morales-Oyarvide V, Rubinson DA, Singh H, Perez K, Cleary JM, Clancy TE, Wang J, Mancias JD, Brais LK, Hill ER, Kozak MM, Linehan DC, Dunne RF, Chang DT, Koong AC, Hezel AF, Hahn WC, Shalek AK, Aguirre AJ, Nowak JA, Wolpin BM. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Cancer Res. 2023 Feb 3;83(3):441-455. doi: 10.1158/0008-5472.CAN-22-3050. PMID: 36459568.

2022

Lucas JH, Wang Q, Rahman I. Perfluorooctane Sulfonic Acid Disrupts Protective Tight Junction Proteins via Protein Kinase D in Airway Epithelial Cells. Toxicol Sci. 2022 Nov 23;190(2):215-226. doi: 10.1093/toxsci/kfac096. PMID: 36106993; PMCID: PMC9960012.
Dias Costa A, Väyrynen SA, Chawla A, Zhang J, Väyrynen JP, Lau MC, Williams HL, Yuan C, Morales-Oyarvide V, Elganainy D, Singh H, Cleary JM, Perez K, Ng K, Freed-Pastor W, Mancias JD, Dougan SK, Wang J, Rubinson DA, Dunne RF, Kozak MM, Brais L, Reilly E, Clancy T, Linehan DC, Chang DT, Hezel AF, Koong AC, Aguirre AJ, Wolpin BM, Nowak JA. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Clin Cancer Res. 2022 Dec 1;28(23):5167-5179. doi: 10.1158/1078-0432.CCR-22-1125. PMID: 36129461; PMCID: PMC9999119.
Mills BN, Qiu H, Drage MG, Chen C, Mathew JS, Garrett-Larsen J, Ye J, Uccello TP, Murphy JD, Belt BA, Lord EM, Katz AW, Linehan DC, Gerber SA. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy. Clin Cancer Res. 2022 Jan 1;28(1):150-162. doi: 10.1158/1078-0432.CCR-21-2495. Epub 2021 Dec 3. PMID: 34862242; PMCID: PMC8738140.
Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, Morrison AB, Georger M, Jewell R, Calvi LM, Nywening TM, O'Dell MR, Hezel AF, De Las Casas L, Lesinski GB, Yeh JJ, Hernandez-Alejandro R, Belt BA, Linehan DC. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut. 2022 Jul;71(7):1386-1398. doi: 10.1136/gutjnl-2021-324109. Epub 2021 Aug 19. PMID: 34413131; PMCID: PMC8857285.

2021

Chiodin G, Allen JD, Bryant DJ, Rock P, Martino EA, Valle-Argos B, Duriez PJ, Watanabe Y, Henderson I, Blachly JS, McCann KJ, Strefford JC, Packham G, Geijtenbeek TBH, Figdor CG, Wright GW, Staudt LM, Burack R, Bowden TA, Crispin M, Stevenson FK, Forconi F. Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood. 2021 Oct 28;138(17):1570-1582. doi: 10.1182/blood.2021012052. PMID: 34424958; PMCID: PMC8554650.
Valle-Argos B, Chiodin G, Bryant DJ, Taylor J, Lemm E, Duriez PJ, Rock PJ, Strefford JC, Forconi F, Burack RW, Packham G, Stevenson FK. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. Sci Rep. 2021 Jun 3;11(1):11676. doi: 10.1038/s41598-021-91112-7. PMID: 34083646; PMCID: PMC8175722.
Palacios F, Yan XJ, Ferrer G, Chen SS, Vergani S, Yang X, Gardner J, Barrientos JC, Rock P, Burack R, Kolitz JE, Allen SL, Kharas MG, Abdel-Wahab O, Rai KR, Chiorazzi N. Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. Leukemia. 2021 Apr;35(4):1037-1052. doi: 10.1038/s41375-020-01115-y. Epub 2021 Jan 27. PMID: 33504942; PMCID: PMC8024198.

2019

Mills BN, Connolly KA, Ye J, Murphy JD, Uccello TP, Han BJ, Zhao T, Drage MG, Murthy A, Qiu H, Patel A, Figueroa NM, Johnston CJ, Prieto PA, Egilmez NK, Belt BA, Lord EM, Linehan DC, Gerber SA. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment. Cell Rep. 2019 Oct 8;29(2):406-421.e5. doi: 10.1016/j.celrep.2019.08.095. PMID: 31597100; PMCID: PMC6919969.